Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
Animals
Cell Differentiation
Cell Line, Tumor
Epithelioid Cells
/ metabolism
Female
GPI-Linked Proteins
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Mesothelin
Mesothelioma
/ genetics
Mice, Inbred BALB C
Mice, Nude
Oncogene Proteins
/ genetics
Phenotype
Sarcoma
/ genetics
Signal Transduction
ERC/mesothelin
Epithelioid type
Histological reversibility
Mesothelioma
Sarcomatoid type
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
16 Jul 2020
16 Jul 2020
Historique:
received:
29
01
2020
accepted:
08
07
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
10
6
2021
Statut:
epublish
Résumé
Mesothelioma is histologically divided into three subgroups: epithelioid, sarcomatoid, and biphasic types. The epithelioid or sarcomatoid type is morphologically defined by polygonal or spindle-like forms of cells, respectively. The biphasic type consists of both components. It is not yet understood how histological differentiation of mesothelioma is regulated. ERC/mesothelin is expressed in most cases of the epithelioid type, but not in the sarcomatoid type of mesothelioma. Consequently, its expression is well correlated to the histological subtype. We hypothesized that ERC/mesothelin expression influences the histological differentiation of mesothelioma, and tested this hypothesis. We performed studies using the overexpression or knockdown of ERC/mesothelin in mesothelioma cells to examine its effect on cellular morphology, growth kinetics, or migration/invasion activity, in vitro. We then transplanted ERC/mesothelin-overexpressing and control cells into the intraperitoneal space of mice. We examined the effect of ERC/mesothelin overexpression on mouse survival and tumor phenotype. In vitro cell culture manipulations of ERC/mesothelin expression did not affect cellular morphology or proliferation, although its overexpression enhanced cellular adhesion and the migration/invasion activity of mesothelioma cells. The survival rate of mice following intraperitoneal transplantation of ERC/mesothelin-overexpressing mesothelioma cells was significantly lower than that of mice with control cells. The histological evaluation of the tumors, however, did not show any morphological difference between two groups, and our hypothesis was not validated. Unexpectedly, both groups (ERC/mesothelin-overexpressing and control) of mesothelioma cells that were morphologically monophasic and spindle-like in vitro differentiated into a biphasic type consisting of polygonal and spindle-like components in the transplanted tumor, irrespective of ERC/mesothelin expression. These results suggested that the histological transition of mesothelioma between epithelioid and sarcomatoid types may be reversible and regulated not by ERC/mesothelin, but by other unknown mechanisms.
Sections du résumé
BACKGROUND
BACKGROUND
Mesothelioma is histologically divided into three subgroups: epithelioid, sarcomatoid, and biphasic types. The epithelioid or sarcomatoid type is morphologically defined by polygonal or spindle-like forms of cells, respectively. The biphasic type consists of both components. It is not yet understood how histological differentiation of mesothelioma is regulated. ERC/mesothelin is expressed in most cases of the epithelioid type, but not in the sarcomatoid type of mesothelioma. Consequently, its expression is well correlated to the histological subtype. We hypothesized that ERC/mesothelin expression influences the histological differentiation of mesothelioma, and tested this hypothesis.
METHODS
METHODS
We performed studies using the overexpression or knockdown of ERC/mesothelin in mesothelioma cells to examine its effect on cellular morphology, growth kinetics, or migration/invasion activity, in vitro. We then transplanted ERC/mesothelin-overexpressing and control cells into the intraperitoneal space of mice. We examined the effect of ERC/mesothelin overexpression on mouse survival and tumor phenotype.
RESULTS
RESULTS
In vitro cell culture manipulations of ERC/mesothelin expression did not affect cellular morphology or proliferation, although its overexpression enhanced cellular adhesion and the migration/invasion activity of mesothelioma cells. The survival rate of mice following intraperitoneal transplantation of ERC/mesothelin-overexpressing mesothelioma cells was significantly lower than that of mice with control cells. The histological evaluation of the tumors, however, did not show any morphological difference between two groups, and our hypothesis was not validated. Unexpectedly, both groups (ERC/mesothelin-overexpressing and control) of mesothelioma cells that were morphologically monophasic and spindle-like in vitro differentiated into a biphasic type consisting of polygonal and spindle-like components in the transplanted tumor, irrespective of ERC/mesothelin expression.
CONCLUSIONS
CONCLUSIONS
These results suggested that the histological transition of mesothelioma between epithelioid and sarcomatoid types may be reversible and regulated not by ERC/mesothelin, but by other unknown mechanisms.
Identifiants
pubmed: 32677949
doi: 10.1186/s12931-020-01449-2
pii: 10.1186/s12931-020-01449-2
pmc: PMC7364551
doi:
Substances chimiques
Erc protein, human
0
GPI-Linked Proteins
0
Msln protein, mouse
0
Oncogene Proteins
0
Mesothelin
J27WDC343N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
187Références
Ultrastruct Pathol. 1987;11(2-3):251-62
pubmed: 2438833
Am J Clin Pathol. 1998 Sep;110(3):397-404
pubmed: 9728617
Oncology. 2014;86(2):109-16
pubmed: 24457449
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Mol Cancer Res. 2008 Nov;6(11):1755-65
pubmed: 19010822
World J Surg Oncol. 2013 Oct 02;11:252
pubmed: 24088577
World J Gastroenterol. 2014 Jun 14;20(22):6884-96
pubmed: 24944479
Pathol Int. 2009 Mar;59(3):161-6
pubmed: 19261093
Cell Rep. 2019 Mar 5;26(10):2566-2579.e10
pubmed: 30840882
Pathol Int. 2007 Apr;57(4):190-9
pubmed: 17316414
J Biol Chem. 1995 Sep 15;270(37):21984-90
pubmed: 7665620
J Surg Res. 2015 Jun 1;196(1):23-32
pubmed: 25791825
Clin Cancer Res. 2012 May 1;18(9):2478-89
pubmed: 22371455
Clin Cancer Res. 2013 May 1;19(9):2493-502
pubmed: 23493352
Am J Surg Pathol. 2003 Feb;27(2):150-8
pubmed: 12548160
Cancer Res. 2006 Mar 15;66(6):2970-9
pubmed: 16540645
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Oncotarget. 2015 May 30;6(15):13757-71
pubmed: 25970771
Mol Clin Oncol. 2015 Jan;3(1):212-216
pubmed: 25469297
Hum Pathol. 2003 Jun;34(6):605-9
pubmed: 12827615
APMIS. 2013 Jan;121(1):1-10
pubmed: 23030626
Sci Rep. 2013;3:1870
pubmed: 23694968
Mod Pathol. 2016 Aug;29(8):824-31
pubmed: 27174587
Histopathology. 1997 Mar;30(3):208-13
pubmed: 9088948
Mod Pathol. 2010 Mar;23(3):470-9
pubmed: 20081811
Int J Gynecol Pathol. 2005 Jan;24(1):67-72
pubmed: 15626919
Am J Surg Pathol. 1986 Jan;10(1):34-47
pubmed: 3953932
J Pathol. 1990 Feb;160(2):103-9
pubmed: 2319390
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
Cancer Res. 2000 Nov 15;60(22):6281-7
pubmed: 11103784
Histopathology. 2003 Mar;42(3):270-9
pubmed: 12605647
PLoS One. 2012;7(4):e33214
pubmed: 22485139
Am J Pathol. 2009 Mar;174(3):762-70
pubmed: 19218339
J Thorac Oncol. 2010 Nov;5(11):1841-8
pubmed: 20975379
Cell Cycle. 2014;13(4):652-65
pubmed: 24345738
J Cancer Res Clin Oncol. 1995;121(9-10):602-5
pubmed: 7559744
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6
pubmed: 10500211
Mod Pathol. 2003 Mar;16(3):192-7
pubmed: 12640097
J Kidney Cancer VHL. 2017 May 22;4(2):19-23
pubmed: 28725540
J Cell Sci. 2010 Jan 15;123(Pt 2):213-24
pubmed: 20048339
Biochem Biophys Res Commun. 2000 Aug 18;275(1):134-40
pubmed: 10944454
Cancer Res. 1995 Mar 15;55(6):1227-31
pubmed: 7882313
Nat Cell Biol. 2012 Dec;14(12):1251-60
pubmed: 23143399
Environ Health Prev Med. 2008 Mar;13(2):60-4
pubmed: 19568882
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Cancer Sci. 2006 May;97(5):387-94
pubmed: 16630136